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CASE SERIESAggressive CD81 epidermotropic cutaneous
T-cell lymphoma associated with homozygous
mutation in SAMHD1
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Mutations in the SAMHD1 (SAM domain and
HD domainecontaining protein 1) gene are impli-
cated in SAMS (stroke, aneurysm, moyamoya, and
stenosis) association,1,2 also described as Aicardi-
Goutieres syndrome type 5 (AGS-5).3 We present a
patient with homozygous germline mutations in
SAMHD1 who subsequently had a CD81 aggressive
epidermotropic cutaneous T-cell lymphoma (CTCL).
CASE REPORT
A 29-year-old Amish woman with intellectual
disability and arthritis caused by the homozygous
mutation c.1411-2A [ G in the SAMHD1 gene
(identified by Xin et al1), presented with fever,
cervical lymphadenopathy, and a diffuse rash. The
rash began 8 weeks before presentation and
consisted of reddish-brown scaly plaques on the
chest, abdomen, and back, which were treated with
topical steroids by her primary physician. She then
became acutely ill and was admitted to the medical
intensive care unit of our institution for circulatory
shock and hypoxemic respiratory failure.
On examination by the dermatology service, the
patient had diffuse, red-brown, circinate, coalescing,
scaly plaques involving the trunk, proximal extrem-
ities, and face (Fig 1, A). A 3-cm 3 3-cm red-purple,
exophytic tumor was noted on the right posterior
thigh (Fig 1, B). Joint examination found deformities
of the bilateral hands without active synovitis.
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sedimentation rate, elevated C-reactive protein,
positive antinuclear antibodies with 1:10,240 titer,
positive antiedouble-stranded DNA antibodies, and
positive antichromatin antibodies. Blood, lower
respiratory, and urine cultures were negative.
Computed tomography of the neck, chest, abdomen,
and pelvis showed bilateral pulmonary infiltrates
and cervical, axillary, retroperitoneal, and gastro-
hepatic lymphadenopathy.
Skin biopsy from the abdomen showed significant
exocytosis of lymphocytes with mildly enlarged
hyperchromatic nuclei without significant cyto-
plasm. Some lymphocytes were surrounded by clear
halos. There was also a moderate superficial and
mid-dermal interstitial and periadnexal lymphocytic
infiltrate (Fig 2). Flow cytometry from affected skin
found a population of atypical T cells (32% of all
events) that were CD21, CD31, CD4, CD71, CD81,
CD25dim, CD26dim, CD56dim, CD30, HLA-DR,
CD45RO, and CD45RA. The cells were T-cellCase Medical Center, Cleveland, OH 44106. E-mail: Meg.Gersten
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Fig 1. Aggressive CD81 epidermotropic CTCL. Cutaneous
findings on initial presentation from the abdomen (A) and
right posterior thigh (B).
Fig 2. Aggressive CD81 epidermotropic CTCL. Histopa-
thology from lesional skin shows significant exocytosis of
normal-size atypical lymphocytes. The lymphocytes
stain with antibodies against CD3 and CD45RB, without
significant CD4 or CD8 staining. (Hematoxylin-eosin stain;
original magnification: 340.)
JAAD CASE REPORTS
JULY 2015
228 Merati et alreceptor (TCR)-a/b positive and did not react with
any antibodies used in the TCR-Vb analysis, consis-
tent with an abnormal clonal T-cell population.
Peripheral blood flow cytometry found no evidence
of a peripheral lymphoproliferative disorder. TCR-g
chain gene rearrangement from affected skin was
negative.
Based on these results, an aggressive CD81
epidermotropic CTCL was diagnosed. Lymph node
biopsy was declined, as it would not change
management, and because of severe thrombocyto-
penia, it represented an unnecessary risk to the
patient. The patient’s family declined treatment
with systemic chemotherapy, and she subsequently
died under hospice care.DISCUSSION
SAMS association was first described in the
Old Order Amish in 2011. The clinical phenotype ishighly heterogeneous, ranging from normal cogni-
tive development to severe intellectual impairment
and early death from recurrent strokes.1 It is likely
that AGS-5 and SAMS association might be the same
entity,3 although most patients from the Amish
cohort, particularly the mildly affected patients, do
not fit the clinical spectrum of AGS-5.2 The clinical
features of AGS-5 include progressive encephalopa-
thy, basal ganglia calcification, whitematter changes,
and cerebrospinal fluid abnormalities of lymphocy-
tosis and elevated interferon alfa levels.4-6
The SAMHD1 protein degrades the intracellular
pool of deoxynucleoside triphosphates, maintaining
genomic stability and the innate immune system.7
SAMHD1 is upregulated in response to viral
infections and is a restriction factor for HIV-1
infection.8 Absence of SAMHD1 causes an imbalance
in DNA precursors, which acts as a danger signal to
the innate immune system, triggering a type I
interferon immune response.7
Activation of the innate immune system plays a
central role in SAMS association/AGS-5 and may lead
to autoimmunity. Many of the symptoms of SAMS
association overlap with autoimmune conditions
such as vasculitis, systemic lupus erythematosus
(SLE), rheumatoid arthritis, and mixed connective
tissue disease, and AGS is associated with systemic
autoimmunity and SLE.1,6 Our patient met 4 of 11
American College of Rheumatology classification
criteria required for the diagnosis of SLE (arthritis,
thrombocytopenia, positive antinuclear antibodies
and antiedouble-stranded DNA antibodies).
Genomic instability caused by SAMHD1 muta-
tions may lead to increased mutagenesis and cancer
development. SAMHD1 somatic mutations have
been identified in 11% of refractory cases of chronic
lymphocytic leukemia and in lung adenocarcinoma;
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cancers. Recently, Clifford et al8 and de Silva et al9
found decreased SAMHD1 expression in 8 patients
with Sezary syndrome and 1 with advanced-stage
mycosis fungoides.
Aggressive CD81 epidermotropic CTCL is a rare
subtype associated with a poor prognosis. Median
expected lifespan from diagnosis is 22.5 to
33 months, with an 18% chance of 5-year survival.
Tumor markers CD2 and CD71 appear to predict a
more aggressive clinical course.10 Our patient’s CTCL
was CD21 and CD71. Although CD81 CTCL is often
clonal,10 our patient did not have TCR-g gene
rearrangement. Potential explanations include
insufficient representation of the clone, genetic
instability leading to deletion of portions of the
TCR-g gene, or other unknown factors.
The absence of prior reports of CTCL in patients
with homozygous mutations of SAMHD1 could
relate to the rarity of AGS-5 or SAMS association
and the reduced lifespan caused by recurrent
cerebrovascular accidents seen in these patients.
Along with de Silva et al,9 our case provides further
evidence for a possible link between SAMHD1
deficiency and CTCL. Additional studies to further
characterize the role of SAMHD1 in the pathogenesis
of CTCL are indicated.
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